End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Covance : Dow, S&P 500 close slightly lower; semis boost Nasdaq | RE |
2014 | Covance : LabCorp to pay $6.1 billion for drug trial company Covance | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Corporate Officer/Principal | - | 23-03-05 | |
Hong Gang Bi
PRN | Corporate Officer/Principal | - | 07-07-31 |
Corporate Officer/Principal | 63 | 12-06-17 | |
Thomas G. Turi
PRN | Corporate Officer/Principal | - | 08-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Eisenberg
BRD | Director/Board Member | 63 | 15-02-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 82,842,141 | 56,052,052 ( 67.66 %) | 25,882,990 ( 31.24 %) | 67.66 % |
Company contact information
Labcorp Drug Development, Inc.
206 Carnegie Center
08540-6233, Princeton
+336-584-5171
http://www.covance.comSector
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- Stock
- Company Covance Inc.